<DOC>
	<DOCNO>NCT00568178</DOCNO>
	<brief_summary>The purpose study evaluate effect losartan proteinuria pediatric patient .</brief_summary>
	<brief_title>An Extension Study Designed Assess Effects Losartan Proteinuria Pediatric Populations ( MK-0954-326 AM1 , EXT1 ( AM2 ) )</brief_title>
	<detailed_description>The study include 12-week double-blind treatment phase 36-month open-label extension phase . Participants complete discontinued initial 12-week phase study opt participate open label extension phase randomize either losartan enalapril dose investigator 's choose duration extension . The open label extension design continue 100th participant complete 3 year follow-up .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Participant 1 17 year age Able provide firstmorning urine sample day study Documented history proteinuria associate chronic kidney disease origin Signed consent parent and/or legal guardian Pregnant and/or nursing Requires 2 medication control high blood pressure Has undergone major organ transplantation ( e.g . heart , kidney , liver ) Known sensitivity losartan similar drug , history angioneurotic edema Known sensitivity amlodipine calcium channel blocker Requires cyclosporine treat renal disease ( kidney disease )</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>